pCPA Monthly Trends & Insights – August 31, 2018

pan-Canadian Pharmaceutical Alliance (pCPA): Negotiation Status Update

The August 31, 2018 update has been issued by the pan-Canadian Pharmaceutical Alliance. The key highlights since the last update are:

• 7 negotiations were completed, while none were closed for a total of 235 completed/closed negotiations;
• 9 new drug products have initiated pCPA negotiations, for a total of 48 active negotiations;
• No new drug products were added to the “No pCPA Negotiations” list, for a total of 54 products for which the pCPA has declined to negotiate – collectively or at the provincial-territorial level.

Negotiation Initiation

• 9 new drug products have initiated pCPA negotiations since the last update, for a total of 48 active negotiations

*Approximation: Negotiation initiation date assumed to be mid-month for the purposes of the calculation

Signals Decoded:

With the completion of negotiations for Praluent’s HeFH indication, the pCPA has initiated new negotiations for both Praluent and Repatha to deal with the larger indication for use in patients with atherosclerotic cardiovascular disease. Also, the initiation of negotiations on the three products indicated for Hereditary tyrosinemia type 1 is the latest example of pCPA waiting to initiate talks with “first entrants” and waiting for anticipated competition in order to conduct concurrent negotiations in competitive therapeutic spaces.

Negotiatons Completed/Closed

• 7 negotiations were completed since the last update, for a total of 209 completed negotiations.

*Approximation: Negotiation initiation and completion date assumed to be mid-month for the purposes of the calculation

• No negotiations were closed since the last update, for a total of 26 closed negotiations.

Signals Decoded:

With 7 completed negotiations in August, pCPA has successfully completed LOI’s for 16 files over the summer months, including several that had been active discussion for extended periods of time. Even with this significant summer progress, the number of total files under active pCPA management (files under pCPA consideration + active negotiations) is at an all-time high of 74 files, and remains over 70 for the 5^th consecutive month.

Files Under pCPA Consideration

In addition to the monthly updates to the pCPA website, MORSE Consulting tracks the number of products “under pCPA Consideration” which have been reviewed by CADTH but have not yet been initiated for negotiation or closed without negotiations.

• Nine new drug products received a CDEC or pERC recommendation or notification to implement in August 2018, for a total of approximately 26 products under pCPA Consideration.

*Drug plan submission

To receive updates similar to this one please be sure to sign up for MORSE Signals, our free e-mail newsletter service.